{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:08:38Z","timestamp":1794254918008,"version":"4.9.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508200"],"award-info":[{"award-number":["2023YFC2508200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["87970425"],"award-info":[{"award-number":["87970425"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cytogfr.2024.11.002","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T10:32:02Z","timestamp":1731234722000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["JAK inhibitors in immune regulation and treatment of vitiligo"],"prefix":"10.1016","volume":"80","author":[{"given":"Kewei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-3155","authenticated-orcid":false,"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cytogfr.2024.11.002_bib1","article-title":"Pathogenesis of alopecia areata and vitiligo: commonalities and differences","volume":"25","author":"Hiroki L","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib2","article-title":"Disorganisation of basement membrane zone architecture impairs melanocyte residence in vitiligo","author":"Fei","year":"2024","journal-title":"J. Pathol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib3","article-title":"RCHY1 and OPTN: an E3-ligase and an autophagy receptor required for melanophagy, respectively","author":"Ki Won","year":"2024","journal-title":"Autophagy"},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib4","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"issue":"7891","key":"10.1016\/j.cytogfr.2024.11.002_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/TACG.S435016","article-title":"Vitamin D receptor gene polymorphisms and association with vitiligo in Indonesian population","volume":"16","author":"Maharani","year":"2023","journal-title":"Appl. Clin. Genet"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2016.07.006","article-title":"The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual","volume":"84","author":"Wang","year":"2016","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamadermatol.2024.0021","article-title":"Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients","volume":"160","author":"Renert-Yuval","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib9","article-title":"Clinician-reported outcome measures for the assessment of vitiligo: a scoping review","volume":"37","author":"Nanja","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.11.002_bib10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol."},{"issue":"0) (","key":"10.1016\/j.cytogfr.2024.11.002_bib11","article-title":"Computer-aided assessment of repigmentation rates in vitiligo patients: implications for treatment efficacy - a retrospective study","author":"Zheng","year":"2024","journal-title":"J. Invest Dermatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/bjd\/ljad245","article-title":"Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study, The","volume":"189","author":"Hamzavi","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib13","article-title":"Comorbidity burden among patients with vitiligo in the united states: a large-scale retrospective claims database analysis","volume":"13","author":"Khaled","year":"2023","journal-title":"Dermatol. Ther. (Heide )"},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/gels9060494","article-title":"Optimization of potential nanoemulgels for boosting transdermal glimepiride delivery and upgrading its anti-diabetic activity","volume":"9","author":"Abdallah","year":"2023","journal-title":"Gels"},{"issue":"40","key":"10.1016\/j.cytogfr.2024.11.002_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200421119","article-title":"Genetic adaptation of skin pigmentation in highland Tibetans","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41590-023-01484-3","article-title":"Dynamic mitochondrial transcription and translation in B cells control germinal center entry and lymphomagenesis","volume":"24","author":"Yazicioglu","year":"2023","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib18","article-title":"Facial involvement is reflective of patients' global perception of vitiligo extent","volume":"189","author":"Samar","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib19","article-title":", Transcultural assessment of quality of life in patients with vitiligo","volume":"86","author":"Amrita","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib20","article-title":"The genetic basis of vitiligo","volume":"141","author":"Richard A","year":"2020","journal-title":"J. Invest Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib21","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Ying","year":"2016","journal-title":"Nat. Genet"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib22","article-title":"Inverse relationship between polygenic risk burden and age of onset of autoimmune vitiligo","author":"Genevieve H L","year":"2024","journal-title":"Am. J. Hum. Genet"},{"issue":"9","key":"10.1016\/j.cytogfr.2024.11.002_bib23","article-title":"The use of platelet-rich plasma in wound healing and vitiligo: a systematic review and meta-analysis","volume":"29","author":"Zhi","year":"2023","journal-title":"Ski. Res Technol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib24","article-title":"Evaluation of IL-38, a newly-introduced cytokine, in sera of vitiligo patients and its relation to clinical features","volume":"14","author":"Zarrabi","year":"2024","journal-title":"Dermatol. Pr. Concept"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib25","article-title":"The many faces of autoimmune-mediated melanocyte destruction in melanoma","volume":"15","author":"Loredana","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2023.06.051","article-title":"Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)","volume":"39","author":"Liu","year":"2023","journal-title":"JAAD Case Rep."},{"issue":"450","key":"10.1016\/j.cytogfr.2024.11.002_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5021\/ad.24.038","article-title":"Up-and-coming drugs for the treatment of vitiligo","volume":"36","author":"Seong","year":"2024","journal-title":"Ann. Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119749","article-title":"Etiopathogenesis and emerging methods for treatment of vitiligo","volume":"24","author":"Iwanowski","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.11.002_bib30","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70i-encoding DNA repigments vitiligo lesions in sinclair swine","volume":"138","author":"Henning","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.11.002_bib31","article-title":"Membranal expression of calreticulin induced by unfolded protein response in melanocytes: a mechanism underlying oxidative stress-induced autoimmunity in vitiligo","volume":"144","author":"Pu","year":"2024","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib32","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Qi","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12967-023-04293-2","article-title":"Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo","volume":"21","author":"Chang","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib34","doi-asserted-by":"crossref","first-page":"1158883","DOI":"10.3389\/fimmu.2023.1158883","article-title":"Leptin deficiency in CD8(+) T cells ameliorates non-segmental vitiligo by reducing interferon-\u03b3 and Granzyme B","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol."},{"issue":"21","key":"10.1016\/j.cytogfr.2024.11.002_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/nu15214697","article-title":"1,25-dihydroxyvitamin D(3) provides benefits in vitiligo based on modulation of CD8+ T cell glycolysis and function","volume":"15","author":"Wei","year":"2023","journal-title":"Nutrients"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib36","article-title":"Skin interstitial fluid and plasma multiplex cytokine analysis reveals IFN-\u03b3 signatures and granzyme b as useful biomarker for activity, severity and prognosis assessment in vitiligo","volume":"13","author":"Chau Yee","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.104499","article-title":"FDA approves Ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann. Med Surg."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib38","article-title":"Tanshinone IIA alleviates vitiligo by suppressing AKT mediated CD8(+) T cells activation in a mouse model","volume":"34","author":"Diancai","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111779","article-title":"Acceleration of melanocyte senescence by the proinflammatory cytokines IFN\u03b3 and TNF\u03b1 impairs the repigmentation response of vitiligo patients to narrowband ultraviolet B (NBUVB) phototherapy","volume":"211","author":"Dong","year":"2023","journal-title":"Mech. Ageing Dev."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib40","article-title":"Study of the Levels of Cytokines IL-6, TNF-\u03b1, and IFN-\u03b3 in Blood and Skin (Lesional and Uninvolved) of Vitiligo Patients and their Possible Role as Biomarkers","volume":"68","author":"Abhishek","year":"2023","journal-title":"Indian J. Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib41","article-title":"Identification of TNF-\u03b1 as major susceptible risk locus for vitiligo: a systematic review and meta-analysis study in the asian population","volume":"240","author":"Tithi","year":"2024","journal-title":"Dermatology"},{"issue":"18","key":"10.1016\/j.cytogfr.2024.11.002_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12185861","article-title":"Serum inflammatory and oxidative stress markers in patients with Vitiligo","volume":"12","author":"Kassab","year":"2023","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14982","article-title":"Compromised melanocyte survival due to decreased suppression of CD4(+) & CD8(+) resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients","volume":"33","author":"Shah","year":"2024","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12016-021-08916-8","article-title":"Future of therapy for inborn errors of immunity","volume":"63","author":"Perez","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaad.2021.11.001","article-title":"This month in JAAD International: February 2022: vitiligo in melanoma patients treated with antiprogrammed cell death-1 therapies and improved survival","volume":"86","author":"Kantor","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib46","article-title":"Interleukin 1\u03b1 and interleukin 18 in patients with vitiligo - results of a case-control study","volume":"160","author":"Barbara","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.11.002_bib47","article-title":"Repositioning T(H) cell polarization from single cytokines to complex help","volume":"22","author":"Selma","year":"2021","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib48","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","volume":"153","author":"Emma","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib49","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Nasser","year":"2019","journal-title":"Arch. Dermatol. Res"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib50","article-title":", The impact on the quality of life and sleep complaints in a vitiligo sample and the influence of inflammatory cytokines in the interaction between vitiligo and sleep","volume":"176","author":"Ellen M S","year":"2024","journal-title":"Cytokine"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib51","article-title":"A Mendelian randomization study on the causal effects of circulating cytokines on the risk of vitiligo","volume":"11","author":"Chengling","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.11.002_bib52","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Maddalena","year":"2023","journal-title":"J. Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib53","article-title":", Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Tali","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113785","article-title":"A case-control study on immunologic markers of patients with vitiligo","volume":"156","author":"Nieradko-Iwanicka","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib55","article-title":"Presence and the roles of IL-9\/Th9 axis in vitiligo","volume":"34","author":"Sushant","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2024.03.036","article-title":"IL-12\/IL-23-independent function of BATF3-dependent dendritic cells is required for initiation of disease in a mouse model of vitiligo","author":"Frisoli","year":"2024","journal-title":"J. Invest Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib57","article-title":"Serum levels of IL-35, one of the newest members of interleukin-12 family of cytokines, in patients with vitiligo","volume":"14","author":"Y\u0131ld\u0131z","year":"2024","journal-title":"Dermatol. Pr. Concept"},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib58","article-title":"Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8(+) T cells activation via JAK-STAT pathway in vitiligo","volume":"139","author":"Xuguang","year":"2019","journal-title":"Free Radic. Biol. Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib59","article-title":"EGR1 mediated reduction of fibroblast secreted-TGF-\u03b21 exacerbated CD8(+) T cell inflammation and migration in vitiligo","volume":"47","author":"Rong","year":"2023","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib60","article-title":"Melanocyte-specific CD49a(+) CD8(+) T cells in vitiligo lesion potentiate to maintain activity during systemic steroid therapy","volume":"50","author":"Kazunori","year":"2022","journal-title":"J. Dermatol."},{"issue":"14","key":"10.1016\/j.cytogfr.2024.11.002_bib61","article-title":"Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy","volume":"134","author":"Lei","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib62","article-title":"Recent thymic emigrants are biased against the T-helper type 1 and toward the T-helper type 2 effector lineage","volume":"117","author":"Deborah W","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.11.002_bib63","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030338","article-title":"T helper cell differentiation, heterogeneity, and plasticity","volume":"10","author":"Zhu","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib64","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Charlie","year":"2021","journal-title":"Semin Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib65","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.11.002_bib66","article-title":"Romidepsin and Afatinib abrogate jak-signal transducer and activator of transcription signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma","volume":"144","author":"Bobby B","year":"2024","journal-title":"J. Invest Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib67","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Emma","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231158235","article-title":"Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis","volume":"16","author":"Ernest-Suarez","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"6702","key":"10.1016\/j.cytogfr.2024.11.002_bib69","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.adq1717","article-title":"JAKing up immunity","volume":"384","author":"Gadina","year":"2024","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.11.002_bib70","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/j.1460-2075.1994.tb06422.x","article-title":"Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91)","volume":"13","author":"Greenlund","year":"1994","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib71","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Michael","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14728222.2023.2193329","article-title":"Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection","volume":"27","author":"Xie","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.843784","article-title":"Potential role of chronic physical exercise as a treatment in the development of vitiligo","volume":"13","author":"de Fran\u00e7a","year":"2022","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib74","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13643-024-02522-3","article-title":"Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo","volume":"13","author":"Prani\u0107","year":"2024","journal-title":"Syst. Rev."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13880209.2022.2163406","article-title":"Mechanisms of action of Lycium barbarum polysaccharide in protecting against vitiligo mice through modulation of the STAT3-Hsp70-CXCL9\/CXCL10 pathway","volume":"61","author":"Peng","year":"2023","journal-title":"Pharm. Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib77","article-title":"Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo","volume":"21","author":"Yuqian","year":"2023","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib78","article-title":"Identification and validation of RNA-binding protein SLC3A2 regulates melanocyte ferroptosis in vitiligo by integrated analysis of single-cell and bulk RNA-sequencing","volume":"25","author":"Jingzhan","year":"2024","journal-title":"BMC Genom."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib79","article-title":"Oxidative stress-induced hypermethylation and low expression of ANXA2R: novel insights into the dysfunction of melanocytes in vitiligo","volume":"114","author":"Jiaxi","year":"2024","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib80","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/CCID.S381432","article-title":"Role of HMGB1 in vitiligo: current perceptions and future perspectives","volume":"15","author":"Wei","year":"2022","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2022.05.012","article-title":"Combination of acitretin and narrowband UV-B for the treatment of vitiligo: a new treatment modality with an impact on tissue E-cadherin expression","volume":"88","author":"Ramadan","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib82","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/oby.2007.79","article-title":"Association of common JAK2 variants with body fat, insulin sensitivity and lipid profile","volume":"16","author":"Ge","year":"2008","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib83","doi-asserted-by":"crossref","first-page":"1055958","DOI":"10.3389\/fimmu.2022.1055958","article-title":"Immunometabolism in the pathogenesis of vitiligo","volume":"13","author":"Lyu","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib84","article-title":", JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Marco","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"0) (","key":"10.1016\/j.cytogfr.2024.11.002_bib85","article-title":"Vitiligo: advances in pathophysiology research and treatment development","author":"Zhussipbek","year":"2024","journal-title":"Trends Mol. Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cells12020217","article-title":"Pathogenic Th2 cytokine profile skewing by IFN-\u03b3-responding vitiligo fibroblasts via CCL2\/CCL8","volume":"12","author":"Jin","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib87","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Peter C","year":"2023","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib88","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"Bras. Dermatol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2024.04.009","article-title":"Vitiligo: advances in pathophysiology research and treatment development","author":"Mukhatayev","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with jak inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib91","article-title":"Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review","author":"Amelia","year":"2024","journal-title":"Int J. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib92","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: Part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib93","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib94","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. Reply","volume":"388","author":"David","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib95","doi-asserted-by":"crossref","unstructured":"G. Tavoletti, G. Avallone, C. Conforti, G. Roccuzzo, C. Maronese, M. Mattioli, P. Quaglino, I. Zalaudek, A. Marzano, S. Ribero, S. Alberti-Violetti, Topical ruxolitinib: A new treatment for vitiligo, Journal of the European Academy of Dermatology and Venereology: JEADV 37(11) (2023) 2222-2230.","DOI":"10.1111\/jdv.19162"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40265-024-02027-2","article-title":"Ruxolitinib cream 1.5%: a review in non-segmental vitiligo","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","article-title":"Real-world use of ruxolitinib cream: safety analysis at 1 year","volume":"25","author":"Hu","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib98","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13555-024-01116-0","article-title":"Satisfaction with control of mild to moderate atopic dermatitis with ruxolitinib cream: US physician and patient perspectives","volume":"14","author":"Eichenfield","year":"2024","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib99","article-title":"Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients","volume":"160","author":"Yael","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib100","article-title":"Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors","volume":"204","author":"Alexander S","year":"2024","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.11.002_bib101","article-title":", JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Mark D","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.11.002_bib102","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib103","article-title":"A case of vitiligo combined with systemic lupus erythematosus treated with tofacitinib","volume":"17","author":"Qingxia","year":"2024","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.11.002_bib106","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Cheng","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.11.002_bib107","article-title":"Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis","volume":"189","author":"C\u00e9cile","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib108","article-title":"Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: a case report","volume":"12","author":"Seyyon","year":"2024","journal-title":"SAGE Open Med Case Rep."},{"issue":"0) (","key":"10.1016\/j.cytogfr.2024.11.002_bib109","article-title":"A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo","author":"Zhongyi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"0","key":"10.1016\/j.cytogfr.2024.11.002_bib110","article-title":"Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Magnus","year":"2022","journal-title":"Drug Des. Devel Ther."},{"issue":"20","key":"10.1016\/j.cytogfr.2024.11.002_bib111","article-title":"The role of interferon-\u03b3 in autoimmune polyendocrine syndrome type 1","volume":"390","author":"Vasileios","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib112","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S334727","article-title":"Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata","volume":"16","author":"Ram\u00edrez-Mar\u00edn","year":"2022","journal-title":"Drug Des. Devel Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib113","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.11.002_bib114","article-title":"Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo","volume":"89","author":"Xinhong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib115","unstructured":"Y. Zhu, Z. Shi, Z. Xu, S. Liu, J. Zhang, Q. Wang, Y. Liu, C. Zhang, M. Jiang, L. Xiang, Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series, Journal of the European Academy of Dermatology and Venereology n\/a(n\/a)."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib116","article-title":"Baricitinib is effective in treating progressing vitiligo in vivo and in vitro","volume":"20","author":"Jie","year":"2022","journal-title":"Dose Response"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.11.002_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13113091","article-title":"Therapeutic potential of targeting the JAK\/STAT pathway in psoriasis: focus on TYK2 inhibition","volume":"13","author":"Dragotto","year":"2024","journal-title":"J. Clin. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib119","first-page":"265","article-title":"Employing zero-inflated beta distribution in an exposure-response analysis of TYK2\/JAK1 inhibitor brepocitinib in patients with plaque psoriasis","volume":"51","author":"Tsamandouras","year":"2024","journal-title":"J. Pharm. Pharm."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaad.2023.02.010","article-title":"Narrowband ultraviolet B phototherapy in pediatric vitiligo: a retrospective study","volume":"89","author":"Garza-Mayers","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.11.002_bib121","article-title":"Comparing the efficacy of 308-nm light-emitting diode and 308-nm excimer lamp for treating vitiligo: a randomized controlled trial","volume":"40","author":"Hu","year":"2024","journal-title":"Photo Photo Photo"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib122","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib123","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2023.03.015","article-title":"Consensus on the safety and risks of laser and intense pulse light treatments in patients with vitiligo: an e-delphi study","volume":"89","author":"Post","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"23","key":"10.1016\/j.cytogfr.2024.11.002_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12237486","article-title":"Updates on potential therapeutic approaches for vitiligo: janus kinase inhibitors and biologics","volume":"12","author":"Pala","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.11.002_bib125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajd.14001","article-title":"A review of JAK and IL-23 inhibitors to treat vitiligo","volume":"64","author":"Lee","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.cytogfr.2024.11.002_bib126","article-title":"Human mesenchymal stem cell-derived exosomes promote the proliferation and melanogenesis of primary melanocytes by attenuating the H(2)O(2)-related cytotoxicity in vitro","volume":"17","author":"Yexiao","year":"2024","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.11.002_bib127","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"issue":"6610","key":"10.1016\/j.cytogfr.2024.11.002_bib128","article-title":"Pituitary hormone \u03b1-MSH promotes tumor-induced myelopoiesis and immunosuppression","volume":"377","author":"Yueli","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2024.11.002_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.120549","article-title":"Tofacitinib combined with melanocyte protector \u03b1-MSH to treat vitiligo through dextran based hydrogel microneedles","volume":"305","author":"Liang","year":"2023","journal-title":"Carbohydr. Polym."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:02:17Z","timestamp":1778601737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610124000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":129,"alternative-id":["S1359610124000893"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.11.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors in immune regulation and treatment of vitiligo","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}